Anti-Fungal Treatment Market Research Report: Information by Drug Class (Azoles, Echinocandins, Polyenes, Allylamines, Pyrimidines), Therapeutic Indication (Systemic, Candidiasis, Cryptococcosis, Prophylactic Use of Antifungals, Coccidioidomycosis), Pathogen (Candid, Aspergillus, Cryptococcus, CoccidiodiesImmitis, Zygomycetes, Trichophyton), End Users (Hospitals & Clinics, Dermatology Clinics) and Region (Americas, Europe, Asia-Pacific, and Middle East & Africa) - Forecast till 2030

Anti-Fungal Treatment Market Forecast

The anti-fungal treatment market is expected to cross USD 18.06 Billion by 2030 at a CAGR of 6.10%.

Market Overview:

Fungi are microorganisms that can stay alive in a wide array of environments and can lead to diverse infections in the human body, ranging from superficial skin to systemic infection that enters the body through inhalation. These infections occur in the human body, usually due to high exposure to unhygienic environments of fungus or due to low immune systems.

The antifungal treatment comprises a variety of products, including azoles and echinocandins. The operational efficiency of antifungal business units depends on the sourcing, manufacturing, and marketing of products. Ongoing technological advancements, government regulations, and consumer preferences affect the lucrativeness of the anti-fungal treatment market. The growth of the global antifungal treatment market is attributed to the increasing incidents of fungal infections. Other factors like the increasing prevalence of immunological diseases and the availability of a wide range of products are driving the anti-fungal treatment market growth.

COVID-19 Analysis:

Coronavirus disease negatively impacts global anti-fungal treatment market growth. The global economy could shrink up to 1% in 2020. As per the United Nations, the COVID-19 pandemic is adversely affecting the FDI flows. Manufacturing, local business, and investments have been badly affected by far-reaching social and economic repercussions. The coronavirus crisis is primarily and foremost a public health threat. However, it is also a rising global threat. The coronavirus disease is a major cause of recession in some countries as well as a warning as it held the global annual growth to below 2.5%, which is often considered a recessionary threshold for the world economy. The increasing number of corona cases has become a major threat to the global economy.

The pandemic COVID-19 has had a negative influence on the global antifungal treatment market. On March 11, 2020, the World Health Organization announced the outbreak a pandemic. The COVID-19 pandemic is affecting the global economies and the US and may also directly affect the operations of many companies and third-party players on which the companies rely. The major players focus on different business strategic alliances such as mergers, acquisitions, agreements, and collaborations to manage their business in this pandemic condition. The impact of the COVID-19 pandemic on the global antifungal treatment markets and their financial capability may reduce the company’s ability to access capital, which could badly impact the short-term and long-term liquidity of many players. Abbot company sales fell to USD 7.33 billion from USD 7.98 billion. Apart from this, the company does not yet know the full extent of potential delays or impacts on its business, financing, other activities, healthcare systems, or the global economy. However, these effects could substantially impact the company’s capital resources, liquidity, operations, and business and those of the third parties.

Market Dynamics:

• Increasing prevalence of immunological diseases in the antifungal treatment

The fungal infection mostly occurs in people having low immunity or suffering from immunological diseases. As per the National Institutes of Health, around 23.5 million Americans suffered from autoimmune disease in 2017. In addition, autoimmune diseases are prevalent in the US, affecting around 14.7 million to 23.5 million people, which is 8% of the total population in the US. They were also the leading cause of death among the young population. Moreover, every year around 220,000 cases of cryptococcal meningitis occur worldwide in patients who have AIDS. Thus HIV/AIDS is the major cause of increasing fungal infections in people. Thus, the increasing number of patients suffering from immunological diseases has driven the global anti-fungal treatment market.

• Increasing incidents of fungal infections


• Availability of a wide range of products

Market Restraints

• Side-effects of treatment

In contrast to the remedial effects, the antifungal treatment can have many side effects as well. Some of them include irritation, itching, headache, diarrhea, and anemia. It is also responsible for causing kidney and liver damage. Besides, many antifungal medicines can cause allergic reactions. Thus, they are not prescribed to pregnant women and children. In addition, drugs amphotericin B and flucytosine, used for Candida and Aspergillus spp infection, cause major adverse effects, including hepatotoxicity, nephrotoxicity, and bone marrow depression.

• Presence of misbranded and spurious drugs

Market Opportunities

• Development of new drugs

There are many types of antifungal treatments available in the market. However, many of them have different side effects, and thus, there is a huge opportunity for manufacturers to develop new drugs. Many drugs are not prescribed to pregnant women and children. In addition to advanced topical carriers because of their distinct structural and functional features, they overcome biopharmaceutical challenges associated with conventional drug delivery systems like poor retention and low bioavailability. Nanocarriers often used for topical antifungal medication include Solid-Lipid nanoparticles, Microemulsions, Liposomes, Niosomes, Microsponge, Nanogel, Nanoemulsion, and Micelles. There are enormousopportunities for the development of the anti-fungal treatment market in developing countries. Thus, the development of new drugs can provide huge growth opportunities for the anti-fungal treatment market.

Global Anti-Fungal Treatment Market Share, by Drug Class, 2019 (%)

Source: MRFR Analysis

Value Chain Analysis / Technology Analysis / Regulatory Implications

The value chain analysis for the antifungal treatment comprises five major components that start with the research & product development, followed by manufacturing the products, distribution, sales, and post-sales services.

Broad business models employed by manufacturers in the global antifungal treatment market include manufacturing locally to minimize operational costs. The other business models include importing products and marketing at reasonable costs. The distribution and marketing collaborations are also observed for a direct presence in the global anti-fungal treatment market. For instance, Pfizer Inc.(US) and BasileaPharmaceutica Ltd (Switzerland), a biopharmaceutical company specializing in the research and development of anti-infective and oncological medicines, have entered into an agreement whereby Pfizer will be granted the exclusive commercialization rights in Europe for CRESEMBA (isavuconazole). Similar collaborative decisions are undertaken by leading companies in the global antifungal treatment market.

Segment Overview

The global anti-fungal treatment market has been divided based on drug class, therapeutic indication, pathogens, and end user.

By drug class

• Azoles

Azoles are commonly used drugs for treating fungal diseases and infections. They are most widely used for systemic fungal infections. The azoles that are available for systemic treatment can be classified into two groups, namely, the triazoles and the imidazoles. The triazole antifungal drugs have a five-membered ring of two carbon atoms and three nitrogen atoms.

• Echinocandins

Echinocandins are semisynthetic lipopeptides produced by chemical modification of pneumocandin B0, a natural product of fungi Glarealozoyensis. They inhibit the synthesis of β-D-glucan in fungal cell walls. Echinocandins are the second-most common drugs after azoles, which are used in treating fungal infections. Echinocandins are used for treating systemic fungal infections in immunocompromised patients. These drugs are poorly absorbed in the gastrointestinal tract (GIT) and thus are administered intravenously.

• Polyenes

Polyenes are molecules with multiple conjugated double bonds, and many of the compounds possess antifungal properties. Polyenes antifungal drugs received attention in the 1980s-1990s. Amphotericin B is one of the major products of the polyenes drug class, which was isolated from Streptomyces bacteria in the 1950s.

• Alllamines

Allylamines inhibit squalene epoxidase, which is an enzyme required for the development of fungi cell walls, thus blocking them from growing on human skin. Terbinafine is one of the major drugs used for the treatment of fungal diseases.

• Pyrimidines

Pyrimidines are heterocyclic nitrogenous bases found in DNA and RNA. Flucytosine or 5-fluorocytosine, a type of pyrimidine, is an antifungal medication.

• Others

The others segment includes Terbinafine, Griseofulvin, and Flucytosine. Lamisil is the most prescribed topical antifungal medication after fluconazole for the treatment of systematic antifungals by dermatologists. Thus, the rising prevalence of dermatological diseases is likely to further boost the growth of the segment.

By Therapeutic Indications

On the basis oftherapeutic indications, the anti-fungal treatment market is bifurcated into systemic, candidiasis, cryptococcosis, prophylactic use of antifungals, and coccidioidomycosis.The systemic type accounts for the largest share and is anticipated to register a CAGR of 6.10% from 2022 to 2030.

• Systemic

The systemic segment held the largest share of 33.7% in 2019. The segment is further divided into aspergillosis, geotrichosis, and others. The aspergillosis segment is sub-segmented into sinusitis, otomycosis, keratitis, and onychomycosis. The Candidiasis segment is further categorized into thrush, mucosal candida infections, vaginal candida infections, and other candida infections. The cryptococcosis segment is further segmented into pulmonary cryptococcosis, cryptococcal meningitis, and others. Prophylactic use of the antifungals segment is further divided into cancer patients, transplantation and abdominal surgery patients, infants, and elderly individuals, and others.

• Candidiasis

Candidiasis is a fungal infection caused by yeast belonging to the family genus Candida. More than 20 species of Candida yeast are responsible for causing infection in humans, which being the most common. Thrush Candida albicans is candidiasis that develops in the mouth. However, it may affect other organs in the body, including the vagina, skin, and nails.

• Cryptococcosis

Cryptococcosis is an infection caused by the fungi Cryptococcus neoformans and Cryptococcus gattii. Most people across the globe who develop cryptococcal infections are either HIV-positive or suffering from other immunological diseases.

• Prophylactic Use of Antifungals

Many antifungal drugs are used for treating patients who are undergoing chemotherapy and radiotherapy for cancer and in patients who are immunocompromised because of HIV infection and AIDS. Immunocompromised patients are susceptible to fungal infection.

• Coccidioidomycosis

Coccidioidomycosis or valley fever is an infection caused by the fungus Coccidioides immitis. This type of fungus is found in the southwestern part of the US, northern Mexico, and parts of Central and South America. But recently, it was also found in south-central Washington. It is the major cause of community-acquired pneumonia.

By Pathogen

On the basis ofpathogen, the anti-fungal treatment market is segmented into Candida, Aspergillus, cryptococcus, Coccidioides immitis, Zygomycetes, Trichophyton, others.The Candida segment accounts for the largest share and is projected to reach USD 13,713.26 million by the end of 2027, owing to an unhealthy lifestyle, poor immunity, and an unclean environment. Moreover, there are many more obese persons with diabetes, hypothyroidism, and other inflammatory diseases, and these individuals are therefore more likely to get infected.

• Candida

Candida is a yeast that causes infections in individuals with deficient immune systems. There are over 20 species of Candida yeasts that can cause infection in humans. Candida albicans is the most common of them. Systemic infections of the bloodstream and major organs, particularly in immunocompromised patients, affect over 90,000 people a year in the US. Candida mostly causes fungal infection, candidiasis across the globe.

• Aspergillus

The most common pathogenic species of Aspergillus are Aspergillus fumigatus and Aspergillus flavus, which thrive indoors and outdoors. Aspergillosis is an infection caused by Aspergillus, which majorly develops in people with weakened immune systems or lung diseases.

• Cryptococcus

Cryptococcus neoformans is the major pathogen causing complications in humans and animals. This causes a severe form of meningitis and meningoencephalitis in patients suffering from HIV infection and AIDS. Besides, it was observed that Cryptococcus gattii is responsible for infection in non-immunocompromised people in tropical parts of the continents of Africa and Australia.

• Coccidioides

Coccidioides immitis, a pathogenic fungus found in the southwestern US and parts of Mexico and Central and South America. This fungus is also found in few other areas in the Western Hemisphere. Azoles are a commonly used drug for the treatment of infections caused by these fungi.

• Zygomycetes

Zygomycetes are one of the rare fungi causing infection in humans. Approximately 1,050 species are identified. Zygomycosis is caused by Zygomycete hyphae fungi and majorly occurs in immunocompetent patients. If the diagnosis is not made in the early stages, it may lead to dissemination.

• Trichophyton

Trichophyton is a genus of fungi, which causes ringworm, jock itch, athlete's foot, and other similar infections of nails, skin, and scalp. These fungi majorly affect animals rather than humans. As per incidents, cats are most responsible for passing Trichophyton to humans.

• Others

In the others segment, we have covered blastomycosis, candida auris, histoplasmosis, and others. The availability of few types of clinical methods for the treatment of infections is a significant health issue. A few drug molecules have been produced over the past few decades.

By End User

On the basis of end user, the anti-fungal treatment market is bifurcated into hospitals and clinics, dermatology clinics, and others. The hospitals and clinics segment is projected to reach USD 12,129.08 million by the end of 2027 at the CAGR of 6.62% during the forecast period.

• Hospital& Clinics

Hospitals and clinics are increasingly adopting new and advanced technologies to treat various skin conditions such as scar treatment, stretch mark treatment, and others. The techniques are based on the abrasion of upper skin layers for rejuvenating the skin.

• Dermatology Clinics

Dermatology clinics are the first addressable points for patients suffering from various dermal conditions such as photodamage, acne, and hyperpigmentation. The number of dermatology clinics is increasing due to the rising demands for skincare services. Thus, the revenue generated by the segment is likely to increase during the forecast period.

• Others

The others segment includes research laboratories and academic institutes

Global Anti-Fungal Treatment Market Share, by Region, 2019 (%)

Source: MRFR Analysis

Regional Analysis

The global antifungal treatment market, based on region, has been divided into the Americas, Europe, Asia-Pacific, and Middle East & Africa.

Americas:

The 40.97% market share of the Americas can be attributed to the high prevalence of antifungal diseases, research spending, and the rapid adoption of advanced treatment in the region. The availability of a large research budget is anticipated to increase the grants for researchers to develop novel products for the antifungal treatment market.

Europe:

Europe is projected to exhibit significant growth during the forecast period due to a higher number of patients and the availability of diagnostic and treatment facilities in the region. The accessibility to advanced treatment facilities, rising government initiatives to promote research to find a cure to the increasing number of cases, and growing healthcare expenditure are driving the growth of the antifungal treatment market in the region. Major manufacturers headquartered in the region include Novartis International AG, Sanofi S.A., Merck KGaA, and Bayer AG. A research paper published in 2018 in the US National Library of Medicine analyzed 5142 cases of invasive candidiasis in the UK in 2016.

Asia-Pacific:

The antifungal treatment market in Asia-Pacific is expected to be the fastest-growing. This high growth is mainly attributed to the increasing R&D funding by developing countries such as China and India for the availability of basic treatments. Various other factors that influence the growth of the market include the growing incidence of fungal infections, the increasing availability of online pharmacies, and the growing number of healthcare professionals.

Middle East & Africa:

The market for antifungal treatment is growing at a significant rate in the Middle East & Africa due to the increasing number of companies and subsidiaries in the region offering treatment options.

Competitive Landscape

The global antifungal treatment market is characterized by many global, regional, and local vendors catering to the demand created by a large patient pool in need of treatment. The availability of innovative products is increasing the lucrativeness of the global antifungal treatment market. The global anti-fungal treatment market is moderately fragmented with rising competition, product launches, rising collaborative partnerships, and other strategic decisions undertaken to achieve operational efficiency.

Broad business models employed by manufacturers in the global antifungal treatment market include manufacturing locally to minimize operational costs. The other business models include importing products and marketing at reasonable costs. The distribution and marketing collaborations are also observed for a direct presence in the global anti-fungal treatment market. For instance, Pfizer Inc. and BasileaPharmaceutica Ltd (Switzerland), a biopharmaceutical company specializing in the research and development of anti-infective and oncological medicines, have entered into an agreement whereby Pfizer will be granted the exclusive commercialization rights in Europe for CRESEMBA (isavuconazole). Similar collaborative decisions are undertaken by leading companies in the global antifungal treatment market.

List of Key Companies Covered in this report:

• Pfizer Inc. (US)


• Astellas Pharma Ltd. (Japan)


• Novartis International AG (Switzerland)


• Sanofi S.A. (France)


• Merck KGaA (Germany)


• Bayer AG (Germany)


• Abbott Laboratories (US)


• Janssen Pharmaceuticals (US)


• Gilead Sciences, Inc. (US)


• Cipla Inc. (India)

Recent Developments

• In December2020, Sanofi (France)renewed a new five-year USD 25 million partnership with the WHO to fight Neglected Tropical Diseases.Neglected Tropical Diseases (NTDs) refer to a group of parasitic, bacterial, fungal, and viral diseases that affect or threaten over one billion people worldwide


• In August2020, Bayer (Germany)aimed for 40% more output at the Beijing production site with a new USD 59 million production unit at the Beijing Economic-Technological Development Area.

The study covers the existing short-term and long-term market effect, helping decision-makers to draught short-term and long-term plans for businesses by region. The report covers major regions in the Americas, Europe, Asia-Pacific, and Middle East & Africa. The report analyzes market drivers, restraints, opportunities, challenges, Porter's Five Forces, Value Chain, and impact of COVID-19 on the market.

Scope of the Report & Segmentation

Anti-Fungal Treatment Market, by Drug Class

• Azoles


• Echinocandins


• Polyenes


• Allylamines


• Pyrimidines


• Others

Anti-Fungal Treatment Market, by therapeutic Indications

• Systemic
  
  
  
  • Aspergillosis
    
    
    
    • Onychomycosis
    
    
    • Sinusitis
    
    
    • Keratitis
    
    
    • Otomycosis
    
    
    
    
  
  
  • Geotrichosis
  
  
  • Others
  
  
  
  


• Candidiasis
  
  
  
  • Thrush
  
  
  • Mucosal Candida infections
  
  
  • Vaginal Candida infections
  
  
  • Other Candida infections
  
  
  
  


• Cryptococcosis
  
  
  
  • Pulmonary cryptococcosis
  
  
  • Cryptococcal meningitis
  
  
  • Others
  
  
  
  


• Prophylactic Use of Antifungals
  
  
  
  • Cancer Patients
  
  
  • Transplantation and Abdominal Surgery Patients
  
  
  • Infants
  
  
  
  


• Coccidioidomycosis

Anti-Fungal Treatment Market, by Pathogens

• Candida


• Aspergillus


• Cryptococcus


• Coccidioides Immitis


• Zygomycetes


• Trichophyton


• Others

Anti-Fungal Treatment Market, by End User

• Hospitals & Clinics


• Dermatology Clinics


• Others

Anti-Fungal Treatment Market, by Region

• Americas
  
  
  
  • North America
    
    
    
    • US
    
    
    • Canada
    
    
    
    
  
  
  • Latin America
    
    
    
    • Brazil
    
    
    • Mexico
    
    
    • Rest of Latin America
    
    
    
    
  
  
  
  


• Europe
  
  
  
  • Western Europe
    
    
    
    • Germany
    
    
    • France
    
    
    • UK
    
    
    • Italy
    
    
    • Spain
    
    
    • Rest of Europe
    
    
    
    
  
  
  • Eastern Europe
  
  
  
  


• Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Middle East & Africa
  
  
  
  • Middle East
  
  
  • Africa